Sana Biotechnology (SANA) is back in focus after Mayo Clinic agreed to collaborate on SC451 for type 1 diabetes and invest up to US$50 million, linking clinical expertise with fresh capital support.
MEDP Class Action: Medpace Sued for Securities Fraud After Cancellation Rates Lead to 16% Stock Drop
Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Medpace Holdings Inc. (NASDAQ:MEDP) and certain of the Company's senior executives ...
With data as of April 8, 2026, we examine if Anbio Biotechnology(NNNN) is consistently building momentum based on AAII's A+ Investor Momentum and Value Scores and Grades.
In the book, “Priority Technologies,” MIT faculty analyze how the U.S. can move ahead in multiple key industrial sectors — semiconductors, biotechnology, critical minerals, drones, quantum computing, ...
The US Food and Drug Administration on Thursday approved the first gene therapy for inherited hearing loss, a one-time ...
Wall Street Journal bestselling author, Italian-American singer-songwriter, and gene therapy entrepreneur Patrick Girondi will appear at the Oxford Exchange Book Fair in Tampa on April 23, 2026, from ...
Dr. William A. Haseltine is a distinguished scientist, philanthropist, author, and entrepreneur renowned for his pioneering work in genomics and regenerative medicine. A former Harvard Medical School ...
Deploying AI to sift through massive biological datasets to identify patterns humans may not see is helping to spread medical ...
Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the closing of its initial ...
Q1 2026 Earnings Call April 21, 2026 8:00 AM EDTCompany ParticipantsRachel VatnsdalRainer Blair - President, CEO ...
The first time Eshani Surya wrote about her ulcerative colitis was for a writing class assignment at NYU. She began the short ...
Jefferies LLC, Goldman Sachs & Co. LLC, Evercore ISI, and Guggenheim Securities, LLC acted as the joint book-running managers for the offering. LifeSci Capital LLC acted as passive bookrunner for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results